Well-Established Use Applications: Building a Bibliographic Dossier That Convinces Assessors

A well-established use application under Article 10a of Directive 2001/83/EC lets you replace your own non-clinical and clinical studies with published literature. It is a route to market for old active substances, but only if the literature is assembled and argued with the rigour of a full dossier.

What the legal basis requires

Article 10a allows an applicant to demonstrate that the constituents of a medicinal product have a well-established medicinal use within the Union, with recognised efficacy and an acceptable level of safety. The use must have been established for at least ten years, and the results of tests and trials can be replaced by detailed references to published scientific literature.

The quality part of the dossier (Module 3) is not replaced. You still need full pharmaceutical development, specifications, validation and stability data for your own product.

Where applications go wrong

Assessors do not accept a pile of abstracts. The usual weaknesses are predictable:

  • Literature that concerns a different dose, route, population or formulation from the one applied for.
  • No clear demonstration that the ten-year period of systematic and documented use applies to the exact indication.
  • Selective citation, with unfavourable or negative studies left out of the search strategy.
  • Old publications that cannot support modern endpoints, with no discussion of the limitations.

Designing the literature review

Treat the search as a documented, reproducible exercise: databases searched, search strings, dates, inclusion and exclusion criteria, and a list of excluded papers with reasons. Weigh the quality of each source, not only the number of sources, and explain how the body of evidence supports the proposed posology and indication.

Where the product differs from what the literature describes, for example a new strength or release profile, you may need bridging data, and the application may then move towards a hybrid route. It is better to decide this early than to discover it in a list of questions.

The overviews carry the argument

In a bibliographic application the non-clinical and clinical overviews in Module 2 do most of the persuading. They must justify why the literature is adequate, address safety signals from post-marketing experience and explain how the product information reflects the published evidence. Full texts of the key references belong in Modules 4 and 5.

Timing and planning

Build the literature work into the development timeline early. A systematic search, appraisal and write-up takes real effort, and the quality review of the sources is the stage most often compressed. Agree with the authors of the overviews how conclusions will be tied to individual references, and keep the full texts organised in Modules 4 and 5 so that assessors can verify any statement quickly. Where national authorities offer scientific advice, a short meeting on the adequacy of the literature approach can save a full assessment round. Treat the literature file as a living document that you must be able to defend, line by line, during assessment.

How PQRA helps

PQRA can help you test whether Article 10a is genuinely available for your product, design and document the literature search, write the expert overviews and align the Module 3 data with the procedure you have chosen, whether national, decentralised or mutual recognition.

Contact PQRA to discuss your dossier and procedure.

CATEGORIES:

Uncategorized

Tags:

No responses yet

Αφήστε μια απάντηση

Η ηλ. διεύθυνση σας δεν δημοσιεύεται. Τα υποχρεωτικά πεδία σημειώνονται με *